NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 58 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $19,501 | -22.0% | 38,312 | 0.0% | 0.01% | -12.5% |
| Q3 2022 | $25,000 | -35.9% | 38,312 | 0.0% | 0.01% | -46.7% |
| Q2 2022 | $39,000 | -45.8% | 38,312 | 0.0% | 0.02% | -37.5% |
| Q1 2022 | $72,000 | -61.1% | 38,312 | 0.0% | 0.02% | -57.1% |
| Q4 2021 | $185,000 | -33.2% | 38,312 | 0.0% | 0.06% | -36.4% |
| Q3 2021 | $277,000 | -21.8% | 38,312 | 0.0% | 0.09% | 0.0% |
| Q2 2021 | $354,000 | -25.0% | 38,312 | 0.0% | 0.09% | -8.3% |
| Q1 2021 | $472,000 | -12.6% | 38,312 | 0.0% | 0.10% | -13.5% |
| Q4 2020 | $540,000 | +17.4% | 38,312 | 0.0% | 0.11% | +22.0% |
| Q3 2020 | $460,000 | -27.7% | 38,312 | 0.0% | 0.09% | -51.1% |
| Q2 2020 | $636,000 | -36.7% | 38,312 | -56.6% | 0.19% | -44.6% |
| Q1 2020 | $1,004,000 | -7.6% | 88,185 | 0.0% | 0.34% | +29.7% |
| Q4 2019 | $1,086,000 | – | 88,185 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 3,862,931 | $46,355,000 | 3.30% |
| Opaleye Management Inc. | 1,386,300 | $16,636,000 | 3.25% |
| Fairmount Funds Management LLC | 372,748 | $4,473,000 | 1.90% |
| Redmile Group, LLC | 4,172,686 | $50,072,000 | 0.92% |
| Boxer Capital, LLC | 1,501,058 | $18,013,000 | 0.62% |
| Prosight Management, LP | 66,376 | $797,000 | 0.38% |
| HighVista Strategies LLC | 39,234 | $471,000 | 0.34% |
| Baker Brothers Advisors | 3,821,740 | $45,861,000 | 0.18% |
| Granahan Investment Management | 296,511 | $3,558,000 | 0.12% |
| Sio Capital Management, LLC | 38,312 | $460,000 | 0.09% |